Corticosteroid-sparing effect of  -adrenergic blocking agents in pemphigus vulgaris.
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D000328:Adult; D001623:Betamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010392:Pemphigus / Q000175:diagnosis / Q000188:drug therapy*; D011433:Propranolol / Q000008:administration & dosage* / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D005938:Glucocorticoids; D001623:Betamethasone; D011433:Propranolol